Inhibitors of the HIV aspartyl protease [HIV protease inhibitors (HIV-PIs)] are the cornerstone of treatment for HIV. Beyond their well-defined antiretroviral activity, these drugs have additional effects that modulate cell viability and homeostasis. However, little is known about the virus-independent pathways engaged by these molecules. Here we show that the HIV-PI Nelfinavir decreases translation rates and promotes a transcriptional program characteristic of the integrated stress response (ISR). Mice treated with Nelfinavir display hallmarks of this stress response in the liver, including α subunit of translation initiation factor 2 (eIF2α) phosphorylation, activating transcription factor-4 (ATF4) induction, and increased expression of known downstream targets. Mechanistically, Nelfinavir-mediated ISR bypassed direct activation of the eIF2α stress kinases and instead relied on the inhibition of the constitutive eIF2α dephosphorylation and down-regulation of the phophatase cofactor CReP (Constitutive Repressor of eIF2α Phosphorylation; also known as PPP1R15B). These findings demonstrate that the modulation of eIF2α-specific phosphatase cofactor activity can be a rheostat of cellular homeostasis that initiates a functional ISR and suggest that the HIV-PIs could be repositioned as therapeutics in human diseases to modulate translation rates and stress responses.
ER stress | translation initiation | Nelfinavir | HIV protease inhibitors | PPP1R15B I n mammalian cells, metabolic and environmental stresses, such as viral infection, nutrient deprivation, and perturbation of endoplasmic reticulum (ER) homeostasis, converge on the phosphorylation of the α subunit of translation initiation factor 2 (eIF2α) to trigger an adaptation program known as the integrated stress response (ISR) (1) . Phosphorylation of eIF2α occurs on serine 51 and negatively regulates the guanine nucleotide exchange factor eIF2B, impairing the recycling of eIF2 to its active GTP-bound form (2) . This signaling event inhibits the initiation steps in mRNA translation, leading to a decrease of global translation rates. Concomitantly, the phosphorylation of eIF2α selectively increases the translation of a subset of genes, including the activating transcription factor-4 (ATF4) (3) . Together, translational and transcriptional reprogramming orchestrates the stress response and homeostasis restoration.
The initiation of the ISR relies on four evolutionarily related eIF2α kinases that each senses specific insults and signals by phosphorylating eIF2α (4) . On the other hand, dephosphorylation of eIF2α and subsequent restoration of the translational capacity is emerging as a key event that controls the complete recovery from stress and ISR termination. Two cellular cofactors of the protein phosphatase-1 (PP1c) can specifically reverse the phosphorylation of eIF2α. The first one is GADD34, which is induced by the ISR to specifically direct PP1c to dephosphorylate eIF2α (5) (6) (7) , allowing termination of the response and restoration of the homeostatic pace of translation (7, 8) . The second one is the protein CReP (Constitutive Repressor of eIF2α Phosphorylation), also known as PPP1R15B, that is expressed ubiquitously in unstressed cells and was identified as a key factor maintaining low levels of eIF2α phosphorylation (9, 10) . Molecules that promote the activation of the eIF2α kinases or modulate the dephosphorylation of eIF2α have been identified and are being considered as potential therapeutics in human diseases characterized by loss of cellular homeostasis including cancer, metabolic deregulation, and neurodegenerative diseases (11) (12) (13) .
It is becoming more and more evident that even the most thoughtfully designed drugs elicit promiscuous interaction profiles within cells (14) , and accordingly, many biological effects of these drugs lack a compelling molecular explanation (14, 15) . This is particularly true for molecules such as Nelfinavir that may interact with multiple off-targets (16) . Beyond understanding the off-target effects of the drugs, the study of these molecular mechanisms provides an opportunity to identify cellular pathways of biological relevance. Nelfinavir is an HIV protease inhibitor (HIV-PI) that was developed in the 1990s, and its incorporation into highly active antiretroviral therapy (HAART) led to remarkable suppression of HIV replication in patients. The HIV-PIs were among the first drugs to reach the clinic that were developed with computer technology applied to compound design based on the X-ray structures. Although these drugs were designed to specifically inhibit the HIV aspartyl protease, they display a wide range of activities independently of their ability to target HIV (17, 18) . Clinical trials are underway to evaluate the effectiveness of HIV-PIs on suppressing tumor progression
Significance
The integrated stress response (ISR) is an adaptation pathway that integrates multiple stress signals to decrease translation rates and promote specific transcriptional programs. Modulation of this pathway is emerging as a possible therapeutic strategy in pathologies associated with defects in protein homeostasis. In this paper, the antiviral drug Nelfinavir is found to be a strong and unconventional inducer of the ISR both in vitro and in vivo. This study uncovers an atypical mechanism that can initiate this pathway and provides insights on possible mechanisms underlying the metabolic deregulations observed in Nelfinavir-treated patients. Nelfinavir has been used for years to treat HIV; its repositioning in diseases that would benefit from decreased translation speed could therefore be of interest. (17, 19) . It was proposed that ER stress contributes to their antineoplastic activity (20) (21) (22) . However, a detailed characterization of the stress responses triggered by the HIV-PIs has not been reported.
Here we investigated the mechanisms leading to activation of cellular stress responses in the presence of the HIV-PIs. We found that these inhibitors, such as Nelfinavir, only triggered a partial ER-stress response characterized by the absence of detectable PKR-like endoplasmic reticulum kinase (PERK) or ATF6 activation or accumulation of misfolded proteins within the ER. However, Nelfinavir affected proteostasis by eliciting a robust ISR. It did so by modulating constitutive dephosphorylation of eIF2α, therefore bypassing direct activation of the eIF2α kinases. These findings highlight the relevance of the modulation of eIF2α-specific phosphatase cofactor activity as a mechanism that can sense and respond to perturbations of cellular homeostasis.
Results
The HIV-PIs Trigger a Limited Unfolded Protein Response. To identify stress pathways engaged by the HIV-PIs, we carried out RNA sequencing (RNA-seq) on HeLa cells treated for 6 h with Nelfinavir or its carrier DMSO (Dataset S1). We used a drug concentration in accordance with the levels found in Nelfinavir-treated patients, which can reach 10 μM in the plasma and can be 4-5-fold higher in peripheral blood mononuclear cells (23, 24) . A heat map of mRNA expression revealed a group of genes that were significantly induced upon treatment with Nelfinavir (Fig. 1A) . We then investigated the functional impact of Nelfinavir, using AmiGO software to search for Gene Ontology term enrichment (25) . Response to ER stress was the most significant functional category enriched among Nelfinavir up-regulated genes (Fig. 1B and Dataset S2). This observation is consistent with previous studies reporting the activation of ER-stress-related genes such as GADD34 and CHOP in cells treated with Nelfinavir (20, 21, 26, 27) . To get more insight on the type of response engaged by Nelfinavir, we compared this signature with a dataset dissecting the ER-stress response in mouse embryonic fibroblasts (MEFs) (28) . We found that among the 32 genes up-regulated in both studies, 30 were previously identified in the ER-stress study as targets of the transcription factor ATF4 (28) (Fig. 1C and Dataset S3). Moreover, of the two exceptions, STC2 has also been reported to be an ATF4-induced gene in another study (29) . To confirm these results, we interrogated the expression of a panel of ER-stress-induced genes upon treatment with Nelfinavir. The expression of ATF4-dependent genes such as GADD34, TRIB3, and SESN2 was increased to levels comparable to the expression observed in the presence of Tunicamycin, a glycosylation inhibitor that triggers a classical ERstress response (Fig. 1D) . In contrast, when we extended this analysis to additional ER-stress genes previously shown to be ATF4-independent, such as EDEM, ERdj4, or HERP, we found that Nelfinavir, compared with Tunicamycin, induced no or only weak expression of these transcripts ( Fig. 2A) . Moreover, in the presence of Nelfinavir, we could not detect activation of the ERstress sensor ATF6, as monitored by liberation of its cleaved fragment (Fig. 2B ). We did not observe an effect of Nelfinavir on Tunicamycin-mediated ATF6 cleavage; thus, Nelfinavir does not inhibit the ATF6-specific proteases S1P and S2P (Fig. 2B , lanes 5 and 6). Similarly, Nelfinavir did not promote the accumulation of high-molecular weight complexes containing the ER chaperone BiP (Fig. 2C) , which is usually associated with the presence of misfolded proteins (13, 30) . These findings suggest that Nelfinavir initiates an ATF4-dependent transcriptional program rather than a typical ER-stress response.
We assessed the protein expression of ATF4 and its downstream target CHOP in MEFs treated for 6 h with increasing doses of Nelfinavir. ATF4 expression was efficiently induced at Nelfinavir concentrations above 5 μM (Fig. 3A) . In a time course experiment using 20 μM Nelfinavir, induction of ATF4 occurred as early as 1 h after treatment, indicating that the activation of this stress pathway is a rapid event (Fig. 3B) . This response is sustained over time, as shown in HeLa cells treated for 14 h with increasing concentration of Nelfinavir (Fig. S1 A and B) . Gene induction and ATF4 production was robust and observed above concentration around 2-5 μM. Investigation of a panel of HIVPIs used in the clinic as well as hydroxy-t-butylamidenelfinavir (M8), the active Nelfinavir metabolite, showed that most HIVPIs trigger robust ATF4 expression (Fig. 3C) . Nevertheless, we consistently found that among the HIV-PIs, Nelfinavir initiates the most robust ATF4 activation in all tested mouse and human cell types. Altogether these data indicate that Nelfinavir triggers a transcriptional response mostly characterized by the selective activation of ATF4.
Nelfinavir Induces a Robust ISR. Expression of ATF4 is usually dependent on the phosphorylation of eIF2α at serine 51, the effector branch of the ISR (31) . Compared with the response observed in the presence of ER-stress inducer Tunicamycin, we found that treatment with Nelfinavir triggered a strong and sustained eIF2α phosphorylation and concomitant ATF4 expression (Fig. 3D) . Accordingly, Nelfinavir-mediated ATF4 and CHOP induction was impaired in MEFs homozygous for the Immunoblot for p-eIF2α shows a robust and sustained eIF2α phosphorylation over time with NFR that correlates with ATF4 expression. Tubulin (Tbl) is used as the loading control.
phosphorylation-deficient mutant of eIF2α, eIF2α(S51A) (Fig. 4A) .
To evaluate the contribution of eIF2α phosphorylation to the Nelfinavir-mediated transcriptional program, we carried out RNAseq on eIF2α(WT) or eIF2α(S51A) MEFs treated with DMSO or Nelfinavir. We found that 646 genes were up-regulated at least twofold by Nelfinavir in MEFs ( Fig. 4B and Dataset S4). Most of these genes (84%) were found to require eIF2α phosphorylation for optimal induction by Nelfinavir ( Fig. 4C and Dataset S5), demonstrating that the ISR is the major transcriptional program initiated upon treatment with Nelfinavir. Similar results were obtained by real-time PCR analysis of eIF2α(WT) or eIF2α(S51A) MEFs treated with increasing amounts of Nelfinavir or Tunicamycin (Fig. 4D ). In tumors, eIF2α phosphorylation is often detected in the context of chemotherapy-and radiotherapymediated cell death (32) . We compared Nelfinavir-mediated eIF2α phosphorylation and ATF4 activation with other treatments used or considered as anticancer therapeutics. Compared with the drugs tested, short-term treatment with Nelfinavir elicits a stronger response similar to Bortezomib, an inhibitor of the proteasome that can cause ER stress (Fig. S1C) . Collectively, these findings demonstrate that Nelfinavir is a potent activator of the ISR.
Nelfinavir Promotes the Activation of ATF4 and the ISR in the Liver of Treated Mice. To test whether Nelfinavir triggers the ISR response in vivo, we injected Nelfinavir intraperitoneally as described previously (33) . Mice treated with 100 mg/kg were killed and Nelfinavir concentrations were measured in the serum and liver (Fig. 5A ). We found that serum concentration was in the range of 1,000 μg/L (1.67 μM) to 3,000 μg/L (5 μM), with a median concentration of 1,757 μg/L. A study in treated HIV patients reported median concentrations of Nelfinavir of 1,632 μg/L for patients with Nelfinavir administrated 1,250 mg twice daily and 1,862 μg/L for patients under a 750 mg thrice daily regimen (34) . This indicates that our mouse model recapitulates the concentrations observed in patients. Moreover, Nelfinavir concentrations in the liver reflected the amount found in HeLa cells treated for 6 h with 5-10 μM Nelfinavir (Fig. 5A ), suggesting that in the liver, Nelfinavir can reach concentrations that can trigger an ISR in vitro. We therefore tested ISR activation in treated mice. Compared with vehicle-treated mice, NFR treatment augmented the ATF4 protein level and eIF2α phosphorylation in the liver (Fig.  5B) . Expression of known ISR-dependent genes such as CHOP, CHAC1, as well as ATF4 was significantly increased in the liver of mice treated with 100 mg/kg of Nelfinavir (Fig. 5C ). Through expression studies in MEFs, we found that PPARγ, a nuclear receptor involved in lipid metabolism, previously shown to be under the control of ATF4 in the liver (35) , was induced by Nelfinavir treatment in an ATF4-dependent manner ( Fig. S1D and Dataset S5). Increased PPARγ was also observed in the liver of Nelfinavir-treated mice (Fig. 5D ). We analyzed a few additional metabolic regulators that were identified in the RNA-seq experiments (Datasets S1 and S5) and found increased expression of genes involved in lipid metabolism such as the Apolipoprotein B Receptor (ApoBr), Cholesterol 25-Hydroxylase (Ch25h), and Sterol O-Acyltransferase 2 (Soat2). Together these results indicate that Nelfinavir-mediated ISR can affect gene expression and metabolic responses in vivo.
ISR Activation Bypasses Direct Activation of the eIF2α Kinases. In the context of ER stress, the ISR component of the ER-stress response is mediated by the eIF2α-kinase PERK. To interrogate PERK involvement in mediating Nelfinavir-induced ISR, we treated PERK-sufficient and -deficient MEFs with Nelfinavir or Tunicamycin. As expected, Tunicamycin induced expression of ATF4 and CHOP in a PERK-dependent manner (Fig. 6A , compare lane 5-6 and 11-12, and Fig. 6B ). In contrast, Nelfinavirmediated ISR was unaffected by PERK deficiency (Fig. 6 A and B and Fig. S2A ). These data are consistent with the observation that Nelfinavir triggers only a partial ER-stress-like response and raised the question of the possible involvement of other eIF2α kinases. We analyzed MEFs deficient for PKR, GCN2, and HRI and found that deletion of any of the three eIF2α kinases does not alter Nelfinavir-mediated ISR responses, as measured by Western blot detection of ATF4 and CHOP expression and eIF2α phosphorylation (Fig. 6C) or by quantitative measurement of CHOP mRNA (Fig. 6D ). As expected, the response induced by the well-known ISR stimuli poly(I:C) lipofection, lack of amino acids, or arsenite treatment required PKR, GCN2, and HRI, respectively (Fig. 6C , compare lanes 11 and 12 for each panel). Note that in this experimental setup, poly(I:C) does not induce a detectable increase in ATF4 expression but elicits a strong eIF2α phosphorylation that requires PKR (36) . Next, we silenced the expression of the individual eIF2α kinase in HeLa cells using specific siRNAs. Each siRNA was tested and selected for its ability to diminish eIF2α kinase protein and mRNA expression (Fig. S3A ) and to yield a significant decrease in eIF2α phosphorylation and subsequent ATF4 expression as well as in CHOP mRNA induction upon treatment with the corresponding activating stress signal ( Fig. S3 B and C) . Consistent with the observations made in knockout cells, silencing of each eIF2α kinase individually did not affect Nelfinavir responses, including ATF4 expression, eIF2α phosphorylation (Fig. 6E) , and CHOP transcription (Fig. 6F) . Activation of the eIF2α kinase can be detected by monitoring its phosphorylation status. To detect active eIF2α kinases, we used a Phos-tag reagent, which selectively binds to phosphorylated amino acid residues (37, 38) . Compared with stress signals that specifically triggered activation of each of the eIF2α kinases, we did not detect increased phosphorylation of any of the eIF2α kinases in the presence of Nelfinavir (Fig. 6G) . Intriguingly, these data indicate that Nelfinavir does not promote eIF2α phosphorylation by directly augmenting the activity of the upstream kinases. To test whether Nelfinavir-induced ISR required the eIF2α kinases at all, we silenced all four eIF2α kinases using a mixture of specific siRNAs that was, as for the individual siRNA, tested for its ability to decrease ISR induction by specific stimuli (Fig. S3, 4K conditions) . Reducing the expression of the four eIF2α kinases together reduced the Nelfinavir-mediated ISR (Fig. 6 H and I) . These results indicate that Nelfinavirinduced ISR relies on the redundant and basal activity of eIF2α kinases, without significantly increasing their activity.
eIF2α Dephosphorylation Is Modulated by Nelfinavir. Previous studies identified CReP as a constitutive repressor of eIF2α phosphorylation that mediates basal dephosphorylation of eIF2α by recruiting the phosphatase PP1 (9). We investigated PP1 and CReP expression levels in Nelfinavir-or Tunicamycin-treated samples. Although we observed no differences in CReP expression upon Tunicamycin treatment over time, Nelfinavir triggered a decrease of CReP protein expression as early as 1 h after treatment (Fig. 7A) . Nelfinavirinduced CReP down-regulation was dose-dependent ( Fig. 7B) and correlated with ATF4 activation.
CReP mRNA has recently been shown to be a target of the regulated IRE1α-dependent decay (RIDD) process (39) . We therefore tested Nelfinavir-mediated ISR induction in IRE1α-deficient MEFs. ATF4 and CHOP induction as well as CReP downregulation was not affected in IRE1α-deficient cells compared with control, suggesting that RIDD pathway is not involved in NFRmediated CReP decrease (Fig. S2 B-D) . Accordingly, the level of CReP mRNA was not affected by Nelfinavir treatment (Fig. 7C) , indicating that CReP regulation is likely posttranscriptional.
Importantly, Nelfinavir-mediated CReP reduction was maintained in MEF eIF2αS51A, showing that it occurs upstream of eIF2α phosphorylation and did not depend on subsequent inhibition of protein translation (Fig. 7D ). In line with this result, we found that Nelfinavir decreased CReP levels in the presence of cycloheximide, a general inhibitor of protein translation (Fig.  S4A) . Moreover, proteasome inhibition with MG132 did not significantly affect Nelfinavir-mediated CReP protein decrease (Fig. S4A) . Similarly we found that down-regulation of βTRCP1 and βTRCP2, two E3 ligases that bind and regulate CReP protein levels (40), increased basal CReP levels but did not affect Nelfinavir-mediated ATF4 induction or CReP decrease (Fig.  S4B) . These findings indicate that the Nelfinavir-dependent regulation of CReP is posttranslational and does not involve the classical proteasome-dependent degradation pathway.
PP1 is a key cellular phosphatase that catalyzes dephosphorylation of many proteins in a highly regulated and specific manner (41) . We tested whether Nelfinavir altered PP1 generic activity. First, we did not detect PP1 protein changes upon treatment with Nelfinavir ( Fig. 7 A and D) . Further, PP1 phosphatase activity (42) was not affected in cell extracts of Nelfinavir-treated samples (Fig.  S4C) . Finally, Nelfinavir did not enhance the phosphorylation of the PP1 target histone H2AX (Fig. S4D) . In contrast, treatment with the PP1 inhibitor Caliculin A affected PP1 activity and triggered phosphorylation of both eIF2α and H2AX (Fig. S4 D and  E) . These data indicate that Nelfinavir does not alter the generic activity of PP1. To interrogate the possibility that Nelfinavir regulates the recruitment of the PP1 complex to eIF2α, we generated a cell line expressing an inducible VSV-tagged eIF2α protein.
Immunoprecipitation of VSV-eIF2α revealed decreased PP1 binding to eIF2α in the presence of Nelfinavir (Fig. 7E) . Interestingly, neither Salubrinal nor Guanabenz (two drugs that have been shown to affect eIF2α phosphorylation by targeting PP1 recruitment to eIF2α) (12, 13) affected CReP protein levels (Fig. 7F) . Thus, the previously described experiments all point to inhibition of eIF2α dephosphorylation that correlates with decreased CReP protein levels, as a specific hallmark of the Nelfinavir-mediated stress response. Real-time PCR analysis of the indicated mRNA isolated from the liver of mice injected i.p. for 3 consecutive days with NFR (100 mg/kg; n = 10) or with the vehicle only (n = 10). P values were determined by a one-tailed unpaired Student's t test (**P < 0.01, *P < 0.05).
CReP Is Required for Nelfinavir-Mediated ISR. In accordance with previous results that showed ISR activation in cells expressing an shRNA construct targeting CReP (9) or isolated from CRePdeficient mice (10), we observed increased ATF4 and CHOP expression in unstressed cells transfected with CReP-specific siRNAs, as well as in CReP-deficient MEFs (Fig. 8 A-D) . The transcriptional program triggered by CReP deficiency recapitulates the ISR elicited by Nelfinavir; factors such as PPARγ, CHAC1, and SESN2 were induced, whereas BiP and ERdj4 were not (Fig. 8C) . Moreover, the ISR mediated by CreP deficiency was reduced when expression of the four eIF2α kinases was silenced (Fig. S5) . These data further demonstrate that basal phosphorylation of eIF2α is a default program in unstressed cells that is constitutively inhibited by CReP-PP1 complexes to maintain homeostasis. Interestingly, when we monitored Nelfinavir responses in CReP-silenced or -deficient cells, we found that Nelfinavir still partially increased ATF4 expression (Fig. 8 B and  D) , suggesting that beyond CReP, Nelfinavir may affect an alternative ISR regulatory pathway. Because GADD34 was increased by CReP deficiency (Fig. 8C) , we analyzed ISR activation in GADD34-deficient MEFs transfected with CReP siRNA (Fig.  8E ) as well as in HeLa cells transfected with a combination of GADD34 and CReP siRNAs (Fig. S6) . Nelfinavir no longer increased ATF4 expression in cells deficient for both CReP and GADD34, whereas Tunicamycin treatment, which drives ISR through PERK activation, still induced ATF4 under the same conditions (Fig. 8E ). This result suggests that Nelfinavir affects the GADD34-mediated negative feedback loop and is consistent with the sustained and robust ISR activation observed with Nelfinavir. Because inhibition of translation initiation is a key feature of the ISR and is controlled by the eIF2α phosphorylation status, we quantified the role of CReP in NFR-or Tunicamycin-mediated ISR activation by monitoring protein synthesis. As expected, the mutation in the eIF2α phosphorylation site rescued translation inhibition in the presence of Tunicamycin or Nelfinavir (Fig. 8F) . However, CReP deficiency only affected Nelfinavir-mediated translation inhibition without affecting Tunicamycin-mediated decrease in translation rates (Fig. 8F) . These findings further demonstrate the specific role of CReP in initiating Nelfinavirinduced ISR and identify CReP modulation as a specific mechanism of ISR activation.
Discussion
EIF2α phosphorylation and the ISR are mostly initiated by stress insults that prime specific eIF2α kinases. EIF2α dephosphorylation events, on the other hand, are considered as negative feedback loops that regulate the intensity and duration of the response. Here we identify modulation of eIF2α dephosphorylation and CReP down-regulation as the initiating event driving Nelfinavir-dependent transcriptional reprogramming. Both Nelfinavir and CReP deficiency trigger a comparable response that is only impaired in the absence of the four eIF2α kinases. These results exclude the hypothesis that Nelfinavir activates a unique eIF2α kinase. Instead, they suggest that the four known eIF2α kinases (i.e., PERK, GCN2, HRI, and PKR) have basal and redundant activity by default and that CReP is a key guardian of cellular integrity that keeps the ISR switched off. The finding that the CReP level can be pharmacologically modulated raises the possibility that other cellular mechanisms may regulate CReP activity to trigger this specific cellular stress response. Here we show that Nelfinavir is associated with decreased CReP protein levels, however whether this is the direct cause of ISR activation is unclear. Indeed, our result showing that PP1 association with eIF2α decreases upon NFR treatment (Fig. 7E) suggests that NFR-mediated CReP decline could be an indirect consequence of a functional regulation of the eIF2α phosphatase complex. In line with this idea, we showed that upon NFR treatment, GADD34, the inducible eIF2α-specific cofactor of PP1, is expressed but cannot compensate for the loss of CReP, suggesting that NFR interferes with GADD34 function. Accordingly, GADD34 silencing impaired the remaining NFRmediated ISR activity observed in CReP-deficient cells. It is likely that identification of Nelfinavir's cellular targets will help define the mechanisms controlling CReP levels and phosphatase complex activity. If this mechanism is probably complex and may rely on binding to multiple targets (16) , the common biological properties shared by the HIV-PIs may also reflect their common specific chemical properties. Most HIV-PIs are peptidomimetics that were designed based on a synthetic analog of the peptide bond between phenylalanine and proline at positions 167 and 168 of the gag-pol polyprotein, a target of the HIV protease (43) . Therefore, we cannot exclude that these common structures shared by HIV-PIs could engage a specific proteostasis sensor to initiate the ISR.
Increased eIF2α phosphorylation is associated with several pathophysiological conditions including neurodegeneration, cancer, diabetes, and obesity (44) (45) (46) . Long-term treatment with the HIV-PIs is associated with adverse effects such as hyperlipidemia or hypolipidemia, body fat redistribution, osteopenia and osteoporosis (47), as well as insulin resistance and susceptibility to type II diabetes (48) (49) (50) (51) . Interestingly, loss-of-function mutation in CReP protein leading to decreased PP1 binding and sustained eIF2α phosphorylation has recently been shown to drive β-cell dysfunction and metabolic defects that can lead to diabetes in human (52) . Elevated levels of ISR markers (such as ATF4 or eIF2α phosophorylation) in the liver of NFR-treated mice suggest that activation of this pathway may contribute to the side effects observed in HIV-PI-treated patients. Indeed, ATF4 is known to play a key role in osteoblast differentiation (53) and its transgenic expression in osteoclasts promotes severe osteopenia (54) . Therefore, bone diseases found in HIV-PI-treated patients could be linked to the deregulation of this transcription factor. In addition, these patients present defects in metabolic pathways including lipid metabolism where ATF4 was shown to play an important role (55, 56) . Studies in ATF4-deficient mice have shown that the ATF4 transcriptional program may affect lipolysis and expression of lipogenic genes (57) . Moreover, it was previously reported that mice with enforced expression of an active C-terminal fragment of GADD34 to attenuate eIF2α phosphorylation have decreased expression of key hepatic transcriptional regulators of intermediary metabolism including PPARγ (58) . In line with these findings, we observed that PPARγ is upregulated in liver of mice upon NFR treatment. PPARγ, is a master regulator of key proteins involved in lipid metabolism, vascular inflammation, and proliferation that can affect multiple cell types, including hepatocytes, macrophages, endothelial cells, and vascular smooth muscle cells. Its possible contribution to side effects in HIV patients treated with HIV-PIs is therefore likely multifaceted and may involve different pathways possibly beyond lipid metabolism. We identified other genes related to lipid metabolism whose expression is up-regulated in the liver of NFR-treated mice, including Soat2 (also abbreviated as Acat2), which was also found among the top genes up-regulated in MEFs in an eIF2α phosphorylation-dependent manner. This enzyme contributes to cholesterol ester synthesis in the small intestine and liver and therefore can promote hypercholesterolaemia and atherosclerosis (59) , two metabolic disturbances often observed in HIV-PI-treated patients. All together these data further show that the ISR is a key metabolic regulator that can affect multiple pathways related to lipid metabolism. It is therefore likely that sustained ISR activation may account for some of the metabolic deregulations associated with the use of HIV-PIs in patients. In this context, ISRIB, a small molecule that potently inhibits the effects of eIF2α phosphorylation (60) (61) (62) , could become an interesting therapeutic option to alleviate ISR-associated metabolic alterations in HIV-PI-treated patients. Another important question is whether the HIV-PI-induced ISR could contribute to their antitumoral activity. Numerous clinical trials are underway to address the efficacy of these drugs in a variety of human tumors, but so far the underlying mechanisms are unknown (19) . Whereas induction of ISR by blocking dephosphorylation of eIF2α is an adaptation program that increases the survival of stressed cells (9) , strategies aimed at increasing eIF2α phosphorylation were found to limit cancer cell proliferation and tumor growth (12, 63) . Similarly, in a genomewide functional screen, CReP down-regulation was identified to increase sensitivity to tamoxifen (64) . The outcome of fine-tuning the eIF2α phosphorylation level under intratumoral stresses is likely to affect the balance between death and survival (44, 65, 66) . It is therefore tempting to speculate that sustained pharmacological activation of ISR could modify the cell fate decision process and tilt the balance in favor of death. Thus, a possible contribution for the ISR in mediating Nelfinavir anticancer properties is a plausible hypothesis that needs to be tested.
In addition to promoting ATF4 expression, the ISR decreases translation rates-a feature that could be relevant in human diseases characterized by perturbation of cellular proteostasis, such as protein misfolding and aggregation diseases. Slowing down translation rates can significantly improve protein folding, therefore contributing to reestablishment of homeostasis in these diseases (67) (68) (69) . Drugs such as Salubrinal (11) and Guanabenz (13) or Sephin 1 (70), which were described as selective inhibitors of cellular complexes that dephosphorylate eIF2α, have been considered toward that purpose and showed promising results in animals. Nelfinavir has the advantage of being a rather safe compound with well-known pharmacology; it has been tested and used in thousands of cancer and HIV patients over many years. Our data show that repositioning this compound to promote the ISR and down-regulate translation rates in patients with misfolding and aggregation diseases should be considered ) were treated for 6 h with NFR at the indicated concentration and TM (10 μg/mL) and analyzed by WB for ATF4 expression and eIF2α phosphorylation. (E) GADD34 ΔC/ΔC MEF and WT control cells were transfected for 24 h with nonrelevant (NR) or CReP-specific siRNA and treated for 6 h with NFR or TM (10 μg/mL). WB analysis using indicated antibodies shows that both CReP and GADD34 silencing are required to abolish NFR-mediated eIF2α phosphorylation and ATF4 induction, whereas in the same condition TM is still able to increase the ATF4 level. shown. P values were determined by a one-tailed unpaired Student's t test (***P < 0.001, **P < 0.01, *P < 0.05).
and may represent a new approach to restore folding and homeostasis in these pathologies.
Materials and Methods
High-throughput sequencing, statistical analysis, lentivirus production, cell line infection, BiP aggregation assay, metabolic labeling, siRNA transfection, immunoprecipitation, and phosphatase activity assay are described in SI Materials and Methods.
Cell Culture and Drug Treatment. All cell lines were cultured in DMEM supplemented with 10% (vol/vol) FBS, antibiotics (1% PSN; penicillin 5 mg/mL, streptomycin 5mg/mL, and neomycin 10mg/mL from Gibco-Life Technologies), 1% nonessential amino acids (Gibco-Life Technologies) and 1% L-glutamine (AMIMED, Bioconcept). Cells were not tested for mycoplasma contamination during the study. Each knockout or transgenic MEF cell line was compared with littermate control. Table S1 shows the origin and provider of every MEF cell lines used in these study.
Nelfinavir Mesylate (CAS 159989-65-8) was from Axon Medchem; Ritonavir, Atazanavir, Lopinavir, and Saquinavir were obtained from The NIH AIDS Reagent Program; and Nelfinavir hydroxy-tert-butylamide (M8) and Oxaliplatin were from Santa-Cruz. Tunicamycin, sodium arsenite solution, Rapamycin, and Cycloheximide were from Enzo-Life Sciences. Guanabenz, Salubrinal, Doxycycline, (Z)-4-Hydroxytamoxifen, Etoposide, and MG132 were from Sigma-Aldrich. Calyculin A, Bortezomib, and Imatinib were from LC-Laboratories, and Okadaic acid was from Santa-Cruz. Poly(I:C) HMW (Invivogen) was lipofected using Lipofectamin2000 (Life Technology).
Mice. Animal experiments were approved by the Veterinary Office of the Canton de Vaud and the Animal Ethics Committee (authorization 2390). WT C57BL/6J mice were housed at the University of Lausanne in accordance with local and national guidelines. Female mice 6-8 wk old were randomly distributed in two groups and injected intraperitoneally for 3 consecutive days either with vehicle [4% (vol/vol) DMSO, 5% (vol/vol) PEG, 5% (vol/vol) Tween 80 in saline] or with 100 mg/kg NFR as described previously (33, 71) . Mice were killed 6 h after the last injection, and livers were harvested for protein and mRNA analysis. Experiments were repeated three times with 3-10 mice per group. One representative experiment with three mice per group is shown for Western blot (WB) analysis. One representative experiment with 10 mice per group is shown for mRNA level quantification by real-time PCR.
Measurement of NFR Concentration. The quantification of nelfinavir in plasma, liver tissue, and cells has been performed with the stable isotope labeled internal standard method using an adaptation of the assay by liquid chromatography tandem mass spectrometry developed in our laboratory (72) .
RNA Extraction and RT-PCR. Total RNA from cells and tissues was extracted with PeqGOLD TriFast (PeqLAB) according to the manufacturer's instructions, and cDNA was synthesized with a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). SYBR Green fluorescent reagent and LightCycler480 Real Time PCR System from Roche were used for quantitative RT-PCR. The relative amount of mRNA was calculated by the comparative threshold cycle method with β-actin as control. Primer sequences are described in Table S2 .
siRNA Transfection. Specific and nonrelevant siRNA were purchased from Qiagen and listed in Table S3 . Cells were transfected with Lipofectamine RNAiMAX Transfection Reagent (Life Technology) according to the manufacturer's instructions.
Immunoblot Analysis. Every WB shown in the study is representative of at least three independent experiments performed in the same conditions. Cells and liver protein extracts were prepared with RIPA (radioimmunoprecipitation assay) buffer (50 mM NaCl, 50 mM Tris pH 7,4, 1 mM EDTA, 0.1% SDS, 1% Nonidet P-40, 1% Sodium Deoxycholate) supplemented with protease inhibitors mixture (Roche) and 5 μM MG132 (Sigma-Aldrich). Extracts were separated by SDS/PAGE and transferred to nitrocellulose blotting membranes (Amersham). PERK, PKR, GCN2, and HRI phosphorylation was monitored by Phos-tag SDS/PAGE (38) . The following antibodies were used for immunoblot analysis: anti-ATF4 (Santa Cruz; sc-200), antiphospho-eIF2α (Cell Signaling; #3597S), anti-total-eIF2α (Cell Signaling; #9722S), anti-IRE1α (Cell Signaling; #3294), anti-PERK (Cell Signaling; #3192), anti-HRI (Santa Cruz; sc-30143), anti-GCN2 (Cell Signaling; #3302), anti-PKR (Santa Cruz; sc-6282), anti-CHOP (Cell Signaling; #2895S), anti-Tubulin (Adipogen; F2C), anti-HsCReP (Proteintech Group; 14634-1-AP), anti-GADD34 (Proteintech Group; 10449-1-AP), anti-mouse CReP (kindly provided by David Ron, University of Cambridge, Cambridge, UK) (10), anti-VSV (Sigma-Aldrich; Clone P5D4), anti-PP1 (Santa Cruz; sc-6108), anti-phospho-H2AX (Upstate; 07-164), polyclonal anti-ATF6 (obtained from Laurie H. Glimcher and AnnHwee Lee, Weill Cornell Medical College, New York, NY) (73) , and anti-BiP (Cell Signaling; #3177S).
